Natural killer cells, or NK cells, are a type of white blood cell that can destroy infected or cancerous cells without needing prior exposure to them. They make up roughly 10% of the lymphocytes circulating in your blood and serve as one of the body’s fastest-acting defenses, attacking threats within hours rather than the days or weeks that other immune cells require.
How NK Cells Fit Into the Immune System
Your immune system has two main branches: innate immunity (the defenses you’re born with) and adaptive immunity (the targeted responses your body builds over time). NK cells belong to the innate branch. They’re classified as innate lymphoid cells, meaning they share a family tree with the T cells and B cells of the adaptive immune system but operate by a fundamentally different set of rules.
The key difference is speed and specificity. Adaptive immune cells like T cells need to be “trained” by encountering a specific pathogen before they can fight it. NK cells skip that step entirely. They can recognize and kill a threatening cell the very first time they encounter it, no prior sensitization required. This makes them critical first responders during the earliest hours of an infection, buying time for the slower, more precise adaptive immune response to ramp up.
How NK Cells Identify Threats
Every healthy cell in your body displays a set of identity tags on its surface called MHC class I molecules (in humans, these are also known as HLA class I). Think of them as a molecular ID badge that says “I belong here.” NK cells patrol the body checking for these badges. When they find a cell displaying normal MHC class I, they leave it alone.
The trouble starts when a cell loses its ID badge. Viruses and cancer often cause cells to reduce or stop displaying MHC class I on their surface. This is actually an evasion tactic: by hiding these molecules, infected or cancerous cells try to avoid detection by T cells, which need MHC class I to recognize a target. But this trick backfires with NK cells. When an NK cell encounters a cell missing its MHC class I, the absence itself triggers an attack. This principle, known as the “missing self” hypothesis, was first proposed by immunologist Klas Kärre in the early 1990s and has since been confirmed extensively.
NK cells also detect stress signals. When a cell is under duress from viral infection or cancerous transformation, it often displays “stress-induced” molecules on its surface that are rare on healthy cells. NK cells carry activating receptors that bind to these stress signals, providing a second line of detection beyond just checking for missing ID badges. The final decision to kill or spare a cell comes down to the balance between these activating signals and the inhibitory signals from MHC class I.
How NK Cells Kill
Once an NK cell commits to destroying a target, it uses a method called the granule-exocytosis pathway. NK cells carry tiny packets (granules) loaded with two key proteins: perforin and granzymes. Perforin punches holes in the target cell’s outer membrane, creating entry points. Granzymes then slip through those holes and enter the cell, where they activate a self-destruct sequence that causes the cell to die in a controlled, orderly way. This controlled death, called apoptosis, is cleaner than the cell simply bursting open, which would release its contents and potentially spread an infection or trigger unnecessary inflammation.
NK Cells and Cancer
NK cells are one of the body’s primary tools for catching cancer early. Because cancer cells frequently lose or reduce their MHC class I molecules, they become visible targets for NK cell attack. This surveillance role is particularly important for blood cancers and for catching tumor cells that break away from a primary tumor and travel through the bloodstream, a process that leads to metastasis.
Research in patients with various cancers, including carcinomas, melanoma, gastrointestinal sarcoma, and breast cancer, has found that higher numbers of circulating NK cells correlate with lower metastatic burden. In other words, people with more active NK cell populations tend to have less cancer spread. NK cells are less effective against established solid tumors, partly because the environment inside a solid tumor can suppress NK cell activity, but they play a significant role in intercepting rogue cancer cells before new tumors can take root.
This cancer-fighting ability has made NK cells a major focus of immunotherapy research. Scientists are developing engineered NK cells, similar to the CAR-T cell therapies already in use, that are modified to better target specific cancers. As of mid-2023, 73 clinical trials were registered evaluating these engineered NK cell therapies against various tumors, though most are still in early phases. In one notable 2020 trial targeting blood cancers, 7 patients with relapsed or treatment-resistant leukemia or lymphoma achieved complete remission after receiving engineered NK cells. No commercial NK cell therapy products are available yet, but the pipeline is active and growing.
NK Cells and Viral Infections
NK cells are among the first immune cells to respond when a virus enters the body. They’re particularly important against herpesviruses (including the viruses behind cold sores, chickenpox, and mononucleosis), hepatitis C, HIV, and dengue. During the COVID-19 pandemic, researchers also documented significant NK cell activation in people infected with SARS-CoV-2.
Their role in viral defense works through the same mechanisms used against cancer. Virus-infected cells often downregulate MHC class I (either because the virus manipulates the cell or because the infection disrupts normal cell function), making them targets for the “missing self” detection system. Infected cells also display stress molecules that trigger NK cell activating receptors. By killing infected cells early, NK cells help contain viral spread before T cells have had time to mount a full adaptive response.
NK Cells vs. T Cells
NK cells and cytotoxic T cells (CD8+ T cells) are often compared because both kill target cells. But they use opposite logic. An NK cell checks whether a cell is missing its MHC class I badge. If the badge is gone, the cell dies. A cytotoxic T cell does the reverse: it looks for foreign material displayed on MHC class I. If it finds viral or abnormal proteins presented on that badge, the cell dies. The two systems complement each other beautifully, because a pathogen that hides from one system typically becomes visible to the other.
The other major difference is timing. T cells need days to activate. They must first encounter pieces of a pathogen presented by specialized antigen-presenting cells, then proliferate into an army of clones targeting that specific threat. NK cells need no such preparation. They arrive ready to kill. This makes NK cells the dominant defenders during the first 24 to 72 hours of an infection, while T cells become the dominant force in the days and weeks that follow.
NK cells were long thought to lack immunological memory, the ability to “remember” a previous infection and respond more powerfully the second time. That’s the hallmark of adaptive immune cells like T cells. However, researchers have identified a subpopulation of highly mature, long-lived NK cells that behave similarly to memory cells, responding more efficiently to previously encountered threats. These are sometimes called memory NK cells, and their discovery has blurred the traditional boundary between innate and adaptive immunity.
NK Cells in Pregnancy
One of the more surprising roles for NK cells is in the uterus during early pregnancy. Uterine NK cells are a specialized subtype that accumulates in the lining of the uterus and behaves very differently from the NK cells in your blood. Rather than primarily killing cells, uterine NK cells help remodel the blood vessels that supply the placenta, support fetal development, and create an environment of immune tolerance so the mother’s body doesn’t reject the embryo. They also protect against infections at the implantation site. Disruptions in uterine NK cell function have been linked to pregnancy complications, making them an active area of reproductive medicine research.
Where NK Cells Come From
NK cells develop in the bone marrow, starting as general-purpose stem cells that progressively commit to becoming NK cells through a series of maturation stages. Early precursor cells exist only in the bone marrow, but as they mature, they migrate into the blood, lymph nodes, and spleen. The final stages of development produce two main populations: CD56-bright NK cells, which are potent producers of chemical signaling molecules called cytokines, and CD56-dim NK cells, which are the more cytotoxic variety responsible for most direct cell killing. In healthy adults, NK cells typically number around 250 per microliter of blood, though the normal range spans roughly 80 to 600.